Thyrocare Technologies Ltd
NSE:THYROCARE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Thyrocare Technologies Ltd
Revenue
Thyrocare Technologies Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
Revenue
₹7.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Dr Agarwal's Eye Hospital Ltd
BSE:526783
|
Revenue
₹4.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
29%
|
CAGR 10-Years
13%
|
|
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
Revenue
₹26.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
|
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
|
Revenue
₹6.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Krsnaa Diagnostics Ltd
NSE:KRSNAA
|
Revenue
₹7.2B
|
CAGR 3-Years
16%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
Revenue
₹15.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
Thyrocare Technologies Ltd
Glance View
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.
See Also
What is Thyrocare Technologies Ltd's Revenue?
Revenue
7.9B
INR
Based on the financial report for Dec 31, 2025, Thyrocare Technologies Ltd's Revenue amounts to 7.9B INR.
What is Thyrocare Technologies Ltd's Revenue growth rate?
Revenue CAGR 5Y
12%
Over the last year, the Revenue growth was 21%. The average annual Revenue growth rates for Thyrocare Technologies Ltd have been 15% over the past three years , 12% over the past five years .
